Table 4 SABA bursts and continuous overuse.

From: Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhaler

 

Patients, n (%)

SABA bursts per patient, mean (SD)

Patients with exacerbations, n (%)

Exacerbations, n

All patients

360 (100)

1.32 (1.05)

64 (18)

74

No continuous overuse

256 (71.1)

1.02 (0.97)

34 (13)

41

No bursts

96 (37.5)

0.00 (0.0)

9 (9)

9

Bursts

160 (62.5)

1.63 (0.71)

25 (16)

32

Continuous overuse

104 (28.9)

2.07 (0.84)

30 (29)

33

No bursts

4 (3.8)

0.00 (0.0)

0 (0)

0

Bursts

100 (96.2)

2.15 (0.74)

30 (30)

33

  1. SABA bursts were defined as a daily mean of at least three inhalations in the last two days and an increase in daily mean inhalations in the last two days compared with the previous two weeks. Multiple SABA bursts within a 7-day period were counted as one burst. Continuous SABA overuse was defined as at least two inhalations per week, every week, over the study period.
  2. SABA short-acting beta2-agonist, SD standard deviation.
Back to article page